Emyria gets green light for final trials of CBD pain-distress treatment
Synthetic cannabinoid-based product developer Emyria (ASX: EMD) has been given the green light to proceed with a Phase 3 clinical trial of its first ultra-pure CBD candidate, EMD-RX5, in a major milestone for the company.
The trial, supported by Emyria’s clinical service subsidiary Emerald Clinics, is aimed at assessing the efficacy of two dose strengths of EMD-RX5 to treat the psychological distress of patients suffering from chronic pain.
A successful trial will support Emyria’s registration of EMD-RX5 with the Therapeutic Goods Administration as a Schedule 3, over-the-counter treatment.
Comments
Post a Comment